Araştırma Makalesi
BibTex RIS Kaynak Göster
Yıl 2022, Cilt: 26 Sayı: 6, 1619 - 1635, 28.06.2025
https://doi.org/10.29228/jrp.253

Öz

Kaynakça

  • [1] Ley JP. Masking bitter taste by molecules. Chemosens Percept. 2008. [CrossRef]
  • [2] Sharma S, Lewis S. Taste masking technologies: A review. Int J Pharm Pharm Sci. 2010.
  • [3] Prashant T, Jigna S, Tejal M, Gaurav A. Taste Masking of Pharmaceutical Formulations: Review on Technologies, Recent Trends and Patents. Int J Pharma Bio Sci. 2020. [CrossRef]
  • [4] Vummaneni V, Nagpal D. Taste Masking Technologies: An Overview and Recent Updates. Int J Res Pharm Biomed Sci. 2012.
  • [5] de Freitas LAP. Pharmaceutical applications of spouted beds: A review on solid dosage forms. Particuology. 2019. [CrossRef]
  • [6] Verma U, Mujumdar A, Naik J. Preparation of Efavirenz resinate by spray drying using response surface methodology and its physicochemical characterization for taste masking. Dry Technol. 2020. [CrossRef]
  • [7] Wu X, Yang S, Yang S, Yang X, Wang Y, Liu Y, et al. Preparation method of penicillin V potassium β-cyclodextrin inclusion. Pak J Pharm Sci. 2018. [CrossRef]
  • [8] Gala U, Chauhan H. Taste masking techniques in the pharmaceutical industry. Am Pharm Rev. 2014.
  • [9] Feng J, Guo Z, Wu L, Yin XZ, Wang LB, Yang M, et al. Taste-masking mechanism of layer-by-layer self-assembly coating investigated by synchrotron radiation-based Fourier-transform infrared spectromicroscopy. Yaoxue Xuebao. 2016. [CrossRef]
  • [10] Zhu Y, You X, Huang K, Raza F, Lu X, Chen Y, et al. Effect of taste masking technology on fast dissolving oral film: Dissolution rate and bioavailability. Nanotechnology. 2018.
  • [11] Dorkhan M, Frid A. A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2007.
  • [12] Jagat JM, Kalyan KG, Subir R. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane? Diabetes Metab Syndr Clin Res Rev. 2020. [CrossRef]
  • [13] Nakano Y, Maeda A, Uchida S, Namiki N. Preparation and evaluation of unpleasant taste-masked pioglitazone orally disintegrating tablets. Int J Pharm. 2013. [CrossRef]
  • [14] Jiang D, Luo LL, Wang H. [Effect of sanqidan granule in treating patients of type 2 diabetes mellitus complicated with hypertension]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009. [CrossRef]
  • [15] I. M, K. K, N. I, P. N, K. N, R. B. MR enterography using experimental SPIO oral contrast agent - First experiences. Ces Radiol. 2009.
  • [16] Wei C, Solanki NG, Vasoya JM, Shah AV, Serajuddin ATM. Development of 3D printed tablets by fused deposition modeling using polyvinyl alcohol as polymeric matrix for rapid drug release. J Pharm Sci. 2020. [CrossRef]
  • [17] Luo D, Kim JH, Park C, Oh E, Park JB, Cui JH, et al. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. Int J Pharm. 2017. [CrossRef]
  • [18] Morin G, Briens L. A comparison of granules produced by high-shear and fluidized-bed granulation methods. AAPS PharmSciTech. 2014. [CrossRef]
  • [19] Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm. 2013. [CrossRef]
  • [20] Pawar N, Saha A, Nandan N, Parambil JV. Solution cocrystallization: A scalable approach for cocrystal production. Crystals. 2021. [CrossRef]
  • [21] Haas K, Dohnal T, Andreu P, Zehetner E, Kiesslich A, Volkert M, et al. Particle engineering for improved stability and handling properties of carrot concentrate powders using fluidized bed granulation and agglomeration. Powder Technol. 2020. [CrossRef]
  • [22] Takahashi AI, Lourenço FR, Duque MD, Consiglieri VO, Ferraz HG. Using fluid bed granulation to improve the dissolution of poorly water-soluble drugs. Braz Arch Biol Technol. 2012;55(3):477–84. Available from
  • [23] Shah HG, Dugar RP, Li HH, Dave VS, Dave RH. Influence of punch geometry (head-flat diameter) and tooling type (‘B’ or ‘D’) on the physical–mechanical properties of formulation tablets. Drug Dev Ind Pharm. 2019. [CrossRef]
  • [24] Schulze D. Flow properties of powders and bulk solids (fundamentals). Powder Technol. 2010. [CrossRef]
  • [25] JV A. Pre and Post Compression Studies of Tablets. Inorg Chem An Indian J. 2016.
  • [26] Pandit V, Kashive D, Sharma TK. Formulation and evaluation of novel formulation for diabetes-induced hypertension using modified innate superdisintegrant. J Drug Deliv Ther. 2020. [CrossRef]
  • [27] Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: Applications in biology and nanoscience. J Biomol Tech. 2010.

Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride

Yıl 2022, Cilt: 26 Sayı: 6, 1619 - 1635, 28.06.2025
https://doi.org/10.29228/jrp.253

Öz

Orally disintegrating tablets, over the years, have become the preferred alternative to conventional tablets and capsule dosage forms because of better compliance. These are suitable for special populations like pediatrics, geriatrics, patient with dysphagia, patients with hand tremors, patients with frequent traveling, etc. The focus of this research was to mask the unpleasant taste of type 2 antidiabetic drug “Pioglitazone Hydrochloride” followed by designing an orally disintegrating tablet of the same. Taste masking was accomplished using a pH-independent polymeric dispersion of ethylcellulose i.e. “Surelease E-7-19040” in combination with a Hypromellose-based ready-tocoat film coating system i.e. “Opadry YS-1-19025-A” in a different ratio. Uncoated powder, coated granules, and prepared tablets of Pioglitazone Hydrochloride were investigated for in-vivo taste evaluation and flow as well as compression behavior, Fourier Transform Infrared spectra, scanning electron microscopy, powder X-ray diffraction, and in-vitro dissolution, disintegration properties. The study demonstrated the use of 32 full factorial design study to identify optimal ratio of pore former in Surelease and Opadry polymeric coating combination to achieve desired taste masking of unpleasant Pioglitazone Hydrochloride without any impact on immediate release characterstic of the orally disintegtrating tablet formulation. It further demonstrated that, an increase in pore former concentration resulted in a lower rating by human volunteers indicating relatively more bitterness, however, an increase in percent weight gain resulted in a higher rating by human volunteers indicating efficient taste masking.

Kaynakça

  • [1] Ley JP. Masking bitter taste by molecules. Chemosens Percept. 2008. [CrossRef]
  • [2] Sharma S, Lewis S. Taste masking technologies: A review. Int J Pharm Pharm Sci. 2010.
  • [3] Prashant T, Jigna S, Tejal M, Gaurav A. Taste Masking of Pharmaceutical Formulations: Review on Technologies, Recent Trends and Patents. Int J Pharma Bio Sci. 2020. [CrossRef]
  • [4] Vummaneni V, Nagpal D. Taste Masking Technologies: An Overview and Recent Updates. Int J Res Pharm Biomed Sci. 2012.
  • [5] de Freitas LAP. Pharmaceutical applications of spouted beds: A review on solid dosage forms. Particuology. 2019. [CrossRef]
  • [6] Verma U, Mujumdar A, Naik J. Preparation of Efavirenz resinate by spray drying using response surface methodology and its physicochemical characterization for taste masking. Dry Technol. 2020. [CrossRef]
  • [7] Wu X, Yang S, Yang S, Yang X, Wang Y, Liu Y, et al. Preparation method of penicillin V potassium β-cyclodextrin inclusion. Pak J Pharm Sci. 2018. [CrossRef]
  • [8] Gala U, Chauhan H. Taste masking techniques in the pharmaceutical industry. Am Pharm Rev. 2014.
  • [9] Feng J, Guo Z, Wu L, Yin XZ, Wang LB, Yang M, et al. Taste-masking mechanism of layer-by-layer self-assembly coating investigated by synchrotron radiation-based Fourier-transform infrared spectromicroscopy. Yaoxue Xuebao. 2016. [CrossRef]
  • [10] Zhu Y, You X, Huang K, Raza F, Lu X, Chen Y, et al. Effect of taste masking technology on fast dissolving oral film: Dissolution rate and bioavailability. Nanotechnology. 2018.
  • [11] Dorkhan M, Frid A. A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2007.
  • [12] Jagat JM, Kalyan KG, Subir R. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane? Diabetes Metab Syndr Clin Res Rev. 2020. [CrossRef]
  • [13] Nakano Y, Maeda A, Uchida S, Namiki N. Preparation and evaluation of unpleasant taste-masked pioglitazone orally disintegrating tablets. Int J Pharm. 2013. [CrossRef]
  • [14] Jiang D, Luo LL, Wang H. [Effect of sanqidan granule in treating patients of type 2 diabetes mellitus complicated with hypertension]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009. [CrossRef]
  • [15] I. M, K. K, N. I, P. N, K. N, R. B. MR enterography using experimental SPIO oral contrast agent - First experiences. Ces Radiol. 2009.
  • [16] Wei C, Solanki NG, Vasoya JM, Shah AV, Serajuddin ATM. Development of 3D printed tablets by fused deposition modeling using polyvinyl alcohol as polymeric matrix for rapid drug release. J Pharm Sci. 2020. [CrossRef]
  • [17] Luo D, Kim JH, Park C, Oh E, Park JB, Cui JH, et al. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. Int J Pharm. 2017. [CrossRef]
  • [18] Morin G, Briens L. A comparison of granules produced by high-shear and fluidized-bed granulation methods. AAPS PharmSciTech. 2014. [CrossRef]
  • [19] Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm. 2013. [CrossRef]
  • [20] Pawar N, Saha A, Nandan N, Parambil JV. Solution cocrystallization: A scalable approach for cocrystal production. Crystals. 2021. [CrossRef]
  • [21] Haas K, Dohnal T, Andreu P, Zehetner E, Kiesslich A, Volkert M, et al. Particle engineering for improved stability and handling properties of carrot concentrate powders using fluidized bed granulation and agglomeration. Powder Technol. 2020. [CrossRef]
  • [22] Takahashi AI, Lourenço FR, Duque MD, Consiglieri VO, Ferraz HG. Using fluid bed granulation to improve the dissolution of poorly water-soluble drugs. Braz Arch Biol Technol. 2012;55(3):477–84. Available from
  • [23] Shah HG, Dugar RP, Li HH, Dave VS, Dave RH. Influence of punch geometry (head-flat diameter) and tooling type (‘B’ or ‘D’) on the physical–mechanical properties of formulation tablets. Drug Dev Ind Pharm. 2019. [CrossRef]
  • [24] Schulze D. Flow properties of powders and bulk solids (fundamentals). Powder Technol. 2010. [CrossRef]
  • [25] JV A. Pre and Post Compression Studies of Tablets. Inorg Chem An Indian J. 2016.
  • [26] Pandit V, Kashive D, Sharma TK. Formulation and evaluation of novel formulation for diabetes-induced hypertension using modified innate superdisintegrant. J Drug Deliv Ther. 2020. [CrossRef]
  • [27] Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: Applications in biology and nanoscience. J Biomol Tech. 2010.
Toplam 27 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular İlaç Dağıtım Teknolojileri
Bölüm Articles
Yazarlar

Prashant Thakker

Jigna Shah

Tejal Mehta

Vasant Shetty

Rahul Aware

Ashwin Kuchekar

Yayımlanma Tarihi 28 Haziran 2025
Yayımlandığı Sayı Yıl 2022 Cilt: 26 Sayı: 6

Kaynak Göster

APA Thakker, P., Shah, J., Mehta, T., Shetty, V., vd. (2025). Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride. Journal of Research in Pharmacy, 26(6), 1619-1635. https://doi.org/10.29228/jrp.253
AMA Thakker P, Shah J, Mehta T, Shetty V, Aware R, Kuchekar A. Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride. J. Res. Pharm. Haziran 2025;26(6):1619-1635. doi:10.29228/jrp.253
Chicago Thakker, Prashant, Jigna Shah, Tejal Mehta, Vasant Shetty, Rahul Aware, ve Ashwin Kuchekar. “Development and Evaluation of Taste Masked Orally Disintegrating Tablets of Pioglitazone Hydrochloride”. Journal of Research in Pharmacy 26, sy. 6 (Haziran 2025): 1619-35. https://doi.org/10.29228/jrp.253.
EndNote Thakker P, Shah J, Mehta T, Shetty V, Aware R, Kuchekar A (01 Haziran 2025) Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride. Journal of Research in Pharmacy 26 6 1619–1635.
IEEE P. Thakker, J. Shah, T. Mehta, V. Shetty, R. Aware, ve A. Kuchekar, “Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride”, J. Res. Pharm., c. 26, sy. 6, ss. 1619–1635, 2025, doi: 10.29228/jrp.253.
ISNAD Thakker, Prashant vd. “Development and Evaluation of Taste Masked Orally Disintegrating Tablets of Pioglitazone Hydrochloride”. Journal of Research in Pharmacy 26/6 (Haziran 2025), 1619-1635. https://doi.org/10.29228/jrp.253.
JAMA Thakker P, Shah J, Mehta T, Shetty V, Aware R, Kuchekar A. Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride. J. Res. Pharm. 2025;26:1619–1635.
MLA Thakker, Prashant vd. “Development and Evaluation of Taste Masked Orally Disintegrating Tablets of Pioglitazone Hydrochloride”. Journal of Research in Pharmacy, c. 26, sy. 6, 2025, ss. 1619-35, doi:10.29228/jrp.253.
Vancouver Thakker P, Shah J, Mehta T, Shetty V, Aware R, Kuchekar A. Development and evaluation of taste masked orally disintegrating tablets of pioglitazone hydrochloride. J. Res. Pharm. 2025;26(6):1619-35.